The STTAR-US Study: A Pivotal Study of Transcatheter Tricuspid Annular Repair in the US

NCT06700239 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2025-11-26

No results posted yet for this study

Summary

Purpose of this clinical study is to demonstrate the safety and efficacy of MIA-T system in improving clinical outcomes in symptomatic patients with severe tricuspid regurgitation (TR grade ≥3) despite optimal medical therapy, who have been determined by the site's local heart team to be at intermediate or greater estimated risk for mortality and morbidity with tricuspid valve surgery.

Conditions

  • Tricuspid Regurgitation Functional
  • Tricuspid Regurgitation
  • Severe Tricuspid Valve Regurgitation

Interventions

DEVICE

MIA_T Device

MIA-T Device

Sponsors & Collaborators

  • Micro Interventional Devices

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2027-06-30
Completion
2032-12-31
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06700239 on ClinicalTrials.gov